Thamban Chandrika Nishad, Green Keith D, Houghton Jacob L, Garneau-Tsodikova Sylvie
Department of Pharmaceutical Sciences, University of Kentucky , Lexington, Kentucky 40536-0596, United States.
Department of Medicinal Chemistry and Life Sciences Institute, University of Michigan , Ann Arbor, Michigan 48109-2216, United States.
ACS Med Chem Lett. 2015 Sep 30;6(11):1134-9. doi: 10.1021/acsmedchemlett.5b00255. eCollection 2015 Nov 12.
Despite issues with oto/nephrotoxicity and bacterial resistance, aminoglycosides (AGs) remain an effective and widely used class of antibacterial agents. For decades now, efforts toward the development of novel AGs with potential to overcome some of these problems have been major research focuses. 1-N-Acylation, especially γ-amino-β-hydroxybutyrate (AHB) derivatization, has proven to be one of the most successful strategies for improving the overall properties of AGs, including their ability to avoid certain resistance mechanisms. More recently, 6'-N-acylation arose as another possible strategy to improve the properties of these drugs. In this study, we report on the glycinyl, carboxybenzyl, and AHB mono- and diderivatization at the 1-, 6'-, and/or 4‴-amines of the AGs amikacin, kanamycin A, netilmicin, sisomicin, and tobramycin. We also present the antibacterial activities and the reduced reactivity of AG-modifying enzymes (AMEs) toward these new AG derivatives, and identify the AMEs present in the bacterial strains tested.
尽管存在耳毒性/肾毒性以及细菌耐药性问题,但氨基糖苷类药物(AGs)仍然是一类有效的、广泛使用的抗菌剂。几十年来,开发具有克服其中一些问题潜力的新型AGs一直是主要的研究重点。1-N-酰化,尤其是γ-氨基-β-羟基丁酸(AHB)衍生化,已被证明是改善AGs整体性质(包括其避免某些耐药机制的能力)最成功的策略之一。最近,6'-N-酰化作为另一种改善这些药物性质的可能策略出现。在本研究中,我们报告了在AGs阿米卡星、卡那霉素A、奈替米星、西索米星和妥布霉素的1-、6'-和/或4''' -胺处进行甘氨酰基、羧苄基和AHB单衍生化及双衍生化的情况。我们还展示了这些新型AG衍生物的抗菌活性以及AG修饰酶(AMEs)对其降低的反应性,并鉴定了受试细菌菌株中存在的AMEs。